Blue dyes (eg Patent Blue V, isosulfan blue) used for imaging purposes during surgery are associated with the occurrence of serious allergic reactions, including anaphylaxis. Surgeons are reminded to have competent personnel and emergency facilities available for at least 1 hour after administration of the blue dye.
Sentiment: Strong Buy
The following adverse reactions have been reported associated with the use of Technetium Tc 99m Sulfur Colloid Injection: cardiopulmonary arrest, seizures, anaphylactic shock, hypotension, dyspnea, abdominal pain, fever, chills, bronchospasm, nausea, vomiting, perspiration, redness, urticaria, numbness, dizziness and burning at the injection site.
Several deaths and cases of lung and soft tissue uptake other than RES have been reported in association with the use of Technetium Tc 99m Sulfur Colloid Injection (see WARNINGS).
The size and physical-chemical properties of the sulfur colloid particles formed from the components of the kit may determine the biodistribution of the colloid and its uptake by the RE system. Diseases affecting the RE system may also alter the expected uptake pattern.
Read the CIS-Sulfur Colloid (cis-sulfur colloid) Side Effects Center for a complete guide to possible side effects
Sentiment: Strong Buy
You have more work to do since there are 423 Nuclear pharmacies in the United States
Nuclear Pharmacies in the United States
Get to work sluggard
Some of the replies to my message were blocked. I have blocked a # of posters who I consider lying morons. . Where I live there are a few local papers from some affluent communities. Because of some the content of these papers one of my brilliant friends referred to these papers as papers for the RICH and STUPID. The posters I block are in that category or work for someone in that category because they control some significant money they can manipulate the price and think that they are bright but sooner or later they will have their a-- kicked and won't feel so bright.
1. FDA approves lymphoseek for breast Ca
2. FDA approves lymphoseek for melanoma
3 FDA approves lymphoseek for head and neck Cancer and designates it with orphan status = $
4. China offers $ for study and approval to obtain approval in China
5 UCSF believes it can benefit patients with Karposi's Saecoma
6 Pediatric oncologists believe it holds out promise for pediatric solid tumors
7.NIH offers big $ to study it in cervical cancer
8. CHMP recommends the EU adopt it as the only approved drug for sentinel lymph node detection in 28 countries
9 Top oncologists at many well respected Univ now recommend its use
10. Manocept use in a multitude of diseases, is thought by some of the brightest minds in medicine, will be helpful
4 more questions
1. Do you think sales will be increasing in the next year?
2. WHO THINKS THERE IS NO FUTURE FOR LYMPHOSEEK?
3. Could it be sleazy hedge fund managers trying to protect their 24,000,0000 share short position?
4. Will big pharm negotiate a takeover?
this entire conversation has been put in motion as a part of " short propaganda" negative add campaign 60,000s/15,000,000 s = 0.4% of their holdings
Orphan Drug Definition
An orphan drug is defined in the 1984 amendments of the U.S.Orphan Drug Act
(ODA) as a drug intended to treat a condition affecting fewer than 200,000 persons in the United States, or which will not be profitable within 7 years following approval by the FDA.
Orphan drugs are desperately needed by patients with rare diseases. The
ODA provides for granting special status, orphan drug designation, to a product to treat a rare disease or condition upon request of a sponsor. The product to treat the rare diseaseor condition must meet certain criteria. Orphan designation qualifies the sponsor of the product for:
-Seven-year marketing exclusivity to the first sponsor obtaining FDA approval of a designated drug
-Tax credit equal to 50% of clinical investigation expenses
-Exemption/Waiver of PDUFA application (filing) fees
- Assistance in the drug development process
- Orphan Products Grant funding
Ann Surg Oncol. 2013 Aug;20(8):2590-9. doi: 10.1245/s10434-013-2887-8. Epub 2013 Mar 17.
Comparative evaluation of [(99m)tc]tilmanocept for sentinel lymph node mapping in breast cancer patients: results of two phase 3 trials.
Wallace AM1, Han LK, Povoski SP, Deck K, Schneebaum S, Hall NC, Hoh CK, Limmer KK, Krontiras H, Frazier TG, Cox C, Avisar E, Faries M, King DW, Christman L, Vera DR.
Author information 1Divisions of Surgical Oncology and Plastic Surgery, UCSD Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA. email@example.com
BACKGROUND: Sentinel lymph node (SLN) surgery is used worldwide for staging breast cancer patients and helps limit axillary lymph node dissection. [(99m)Tc]Tilmanocept is a novel receptor-targeted radiopharmaceutical evaluated in 2 open-label, nonrandomized, within-patient, phase 3 trials designed to assess the lymphatic mapping performance.
METHODS: A total of 13 centers contributed 148 patients with breast cancer. Each patient received [(99m)Tc]tilmanocept and vital blue dye (VBD). Lymph nodes identified intraoperatively as radioactive and/or blue stained were excised and histologically examined. The primary endpoint, concordance (lower boundary set point at 90 %), was the proportion of nodes detected by VBD and [(99m)Tc]tilmanocept.
RESULTS: A total of 13 centers contributed 148 patients who were injected with both agents. Intraoperatively, 207 of 209 nodes detected by VBD were also detected by [(99m)Tc]tilmanocept for a concordance rate of 99.04 % (p
Short interest increased, institutions increased long positions = evidenc of the hole the shorts are digging for themselves
If you can't see past a week or so perhaps $1.20-$1.34. If you can see past that time period then NAVB value
= $1.30 +
+ value added by increasing sales ( deeper penetration as SC and blue dye use decreases , increase in indications for other cancers, distribution into EU and other countries in the world0,
+- future increase in price which is a certainty)
+ better management controlling expenses,
+ Manocept and its fantastic potential,
+ value of remainder pipeline including imaging for Alzheimers, and Riggs which are presently ignored,
+ better deals than the Cardinal deal for sales in the rest of the world,
+ partnerships that will occur,
+ the potential of a buyout by big pharm.
+ Don't forget that the shorts, who have been disseminators of disinformation, misinformation (lies) and who have created an emotional environment of negativity by their constant bombing runs will eventually cover
Sentiment: Strong Buy
100,000 shares long at $1.26 downside $40,000 Max upside $70,000- $300,000 or more
100,000 shares short at $1.26 upside $40,000 Max downside if short if you don't cover $100,000- $300,000 and possibly much more
which position would make you more nervous
For the last 1-2 years shorts have been right. Some shorts will see a significant profit , if they cover now. Some will be lucky to break even and I expect some will lose big-time
Do you think their buy point is below $1.00 What is their exit strategy seems to me their risk is increasing and their reward very limited with the possibility in the next 2 years of waking up one morning to a disaster or facing a ground invasion by longs
this ratio seems to be higher by the day why not cover short position now reward in holding the position is very limited, risk in holding the position very high and higher every day ( real expectations of increasing sales for breast cancer and H&N cancer,, increasing sales when approved for more indicatiions, and increasing sales with approved in EU and other countries. Also it is very reasonable to expect more partnerships and their is the real potential of a buyout by big pharm in the future)